Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma.

Cureus · 2023 · PMC10066464 · PMID 37012938

Europe PMC DOI

hedged sentences

0.1050

closest p · 2.1× alpha

0.1050

boldest claim

The sentences

did not reach statistical significancep=0.105not close (p > 0.1)

Surprisingly, overall survival analysis showed that patients on tivozanib had a trend toward lower overall survival compared to patients on sorafenib, although the result did not reach statistical significance (28.8 months vs. 29.3 months; HR, 1.245; 95% CI, 0.954 to 1.624; p=0.105) [ 13 ].

also in 111,027 other papers

showed a trendno p-value reported

Moreover, tivozanib did not show any survival advantage in the TIVO-3 trial, while it showed a trend toward inferior OS in the TIVO-1 trial.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.